Quick Answer
Lucid Diagnostics Inc. reported Operating Income Loss of -$49.64 million for the year ending 2025.
- Lucid Diagnostics Inc. showed a decrease of -7.8% in Operating Income Loss from 2024 to 2025.
- This data is from Lucid Diagnostics Inc.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: -$2.02 million | Q1 2021: -$3.65 million | Q2 2021: -$6.02 million | Q3 2021: -$6.51 million | Q1 2022: -$12.27 million | Q2 2022: -$14.63 million | Q3 2022: -$14.38 million | Q1 2023: -$14.32 million | Q2 2023: -$11.58 million | Q3 2023: -$11.13 million | Q1 2024: -$10.79 million | Q2 2024: -$11.19 million | Q3 2024: -$11.69 million | Q1 2025: -$12.49 million | Q2 2025: -$11.38 million | Q3 2025: -$11.76 million.
- Over the full 6 years of available data (2020 to 2025), Lucid Diagnostics Inc.'s Operating Income Loss has declined by 499.5%.
- Historical annual values: Fiscal year 2025: -$49.64 million | Fiscal year 2024: -$46.05 million | Fiscal year 2023: -$48.48 million | Fiscal year 2022: -$56.25 million | Fiscal year 2021: -$27.42 million | Fiscal year 2020: -$8.28 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: